{
  "slug": "osteoporosis",
  "title": {
    "zh": "骨質疏鬆：亞洲管線與全球對手",
    "en": "Osteoporosis: Asian pipelines and global competitors"
  },
  "answer": {
    "zh": "截至 2026-11-14，亞洲骨質疏鬆藥物參與者包括 Celltrion、Samsung Bioepis 與復宏漢霖，三家公司均有 denosumab 生物相似藥；它們與全球原廠的 romosozumab、abaloparatide 作用機轉不同。本頁將抗骨吸收與促進骨形成路徑分開，沒有把生物相似藥當成新機制藥。",
    "en": "As of 2026-11-14, Asian osteoporosis participants include Celltrion, Samsung Bioepis and Henlius, each with a denosumab biosimilar. Their mechanism differs from the global comparators romosozumab and abaloparatide. This page distinguishes antiresorptive and bone-forming pathways and does not present biosimilars as novel mechanisms."
  },
  "scope": {
    "zh": "聚焦注射生物藥與胜肽；不是所有骨質疏鬆藥物普查。腫瘤骨病劑型不併入骨質疏鬆產品。",
    "en": "Selected injectable biologics and peptides, not a census of all osteoporosis medicines. Oncology bone-disease presentations are kept separate."
  },
  "as_of": "2026-11-14",
  "window_start": "2026-08-17",
  "window_end": "2026-11-14",
  "rows": [
    {
      "id": "bone-celltrion",
      "company": {
        "zh": "Celltrion（韓國）",
        "en": "Celltrion (South Korea)"
      },
      "asset": "CT-P41 / STOBOCLO",
      "asia": true,
      "mechanism": {
        "zh": "抗 RANKL；denosumab 生物相似藥",
        "en": "Anti-RANKL; denosumab biosimilar"
      },
      "stage": {
        "zh": "美國已核准並上市",
        "en": "Approved and launched in the US"
      },
      "indication": {
        "zh": "骨折高風險骨質疏鬆等，依標籤",
        "en": "High-fracture-risk osteoporosis and other labeled indications"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "美國上市公告：STOBOCLO 對應 Prolia；OSENVELT 腫瘤骨病劑型另列。",
        "en": "US launch announcement: STOBOCLO references Prolia; the OSENVELT oncology presentation is distinct."
      },
      "date": "2025-07-07",
      "sources": [
        {
          "url": "https://www.celltrion.com/en-us/company/media-center/press-release/4058",
          "title": "Celltrion US launch",
          "date": "2025-07-08",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "bone-samsung",
      "company": {
        "zh": "Samsung Bioepis（韓國）",
        "en": "Samsung Bioepis (South Korea)"
      },
      "asset": "SB16 / OSPOMYV / OBODENCE",
      "asia": true,
      "mechanism": {
        "zh": "抗 RANKL；denosumab 生物相似藥",
        "en": "Anti-RANKL; denosumab biosimilar"
      },
      "stage": {
        "zh": "美國／歐盟已核准",
        "en": "Approved in the US / EU"
      },
      "indication": {
        "zh": "骨質疏鬆等，依標籤",
        "en": "Osteoporosis and other labeled indications"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "公布 SB16 第三期骨質疏鬆族群的次群分析；非新機制或新核准宣告。",
        "en": "Reported Phase 3 osteoporosis subgroup analyses; not a novel mechanism or new approval announcement."
      },
      "date": "2026-04-17",
      "sources": [
        {
          "url": "https://www.samsungepisholdings.com/en/newsroom/newsroomView.do?idx=541",
          "title": "Samsung SB16 osteoporosis subgroup analysis",
          "date": "2026-04-17",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://www.samsungbioepis.com/en/product/product01.do?index=9",
          "title": "Samsung SB16 approval listing",
          "date": null,
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "bone-henlius",
      "company": {
        "zh": "復宏漢霖／Organon",
        "en": "Henlius / Organon"
      },
      "asset": "HLX14 / BILDYOS",
      "asia": true,
      "mechanism": {
        "zh": "抗 RANKL；denosumab 生物相似藥",
        "en": "Anti-RANKL; denosumab biosimilar"
      },
      "stage": {
        "zh": "北美／歐洲已核准；中國申請審查中",
        "en": "Approved in North America / Europe; China application under review"
      },
      "indication": {
        "zh": "骨質疏鬆等；BILDYOS 劑型",
        "en": "Osteoporosis and other indications; BILDYOS presentation"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "2026 中期簡報列示核准與申請狀態；文件標示 8 月，網址上傳 11 月不當作新事件。",
        "en": "The 2026 interim deck lists approval and filing status; its August cover date is used, not the November upload path."
      },
      "date": "2026-08",
      "sources": [
        {
          "url": "https://www.henlius.com/upload/202611/06/Henlius2026InterimResultsInvestorSlides.pdf",
          "title": "Henlius interim presentation, pp. 25–26",
          "date": "2026-08",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "bone-prolia",
      "company": {
        "zh": "安進",
        "en": "Amgen"
      },
      "asset": "denosumab / Prolia",
      "asia": false,
      "mechanism": {
        "zh": "抗 RANKL 抗體；生物相似藥參照品",
        "en": "Anti-RANKL antibody; reference product"
      },
      "stage": {
        "zh": "已核准",
        "en": "Approved"
      },
      "indication": {
        "zh": "骨質疏鬆等，依標籤",
        "en": "Osteoporosis and other labeled indications"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "第三季全球季銷售 632 百萬美元；公司表示多款生物相似藥已在全球上市。",
        "en": "Q3 global sales were USD 632 million; the company noted multiple biosimilar launches globally."
      },
      "date": "2026-11-03",
      "sources": [
        {
          "url": "https://www.amgen.com/newsroom/press-releases/2026/11/amgen-reports-third-quarter-2026-financial-results",
          "title": "Amgen Q3 2026 results",
          "date": "2026-11-03",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "bone-amgen",
      "company": {
        "zh": "安進／UCB",
        "en": "Amgen / UCB"
      },
      "asset": "romosozumab / EVENITY",
      "asia": false,
      "mechanism": {
        "zh": "抗 sclerostin 抗體",
        "en": "Anti-sclerostin antibody"
      },
      "stage": {
        "zh": "已核准",
        "en": "Approved"
      },
      "indication": {
        "zh": "高骨折風險停經後骨質疏鬆",
        "en": "Postmenopausal osteoporosis at high fracture risk"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "第三季申報顯示 EVENITY 全球季銷售 751 百萬美元；財報事件不代表新增療效。",
        "en": "Q3 filing reports global quarterly EVENITY sales of USD 751 million; a financial event is not new efficacy evidence."
      },
      "date": "2026-11-03",
      "sources": [
        {
          "url": "https://www.amgen.com/newsroom/press-releases/2026/11/amgen-reports-third-quarter-2026-financial-results",
          "title": "Amgen Q3 2026 results",
          "date": "2026-11-03",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "bone-radius",
      "company": {
        "zh": "Radius Health",
        "en": "Radius Health"
      },
      "asset": "abaloparatide / TYMLOS",
      "asia": false,
      "mechanism": {
        "zh": "PTHrP 類似物",
        "en": "PTHrP analog"
      },
      "stage": {
        "zh": "美國已核准",
        "en": "Approved in the US"
      },
      "indication": {
        "zh": "高骨折風險停經後女性；男性增加骨密度",
        "en": "High-fracture-risk postmenopausal women; increased bone density in men"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "DailyMed 標籤於 08-11 更新，包含過敏反應警示；日期在本頁 90 天區間之前。",
        "en": "DailyMed label updated on 08-11, including hypersensitivity warnings; this predates the page’s 90-day window."
      },
      "date": "2026-08-11",
      "sources": [
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8",
          "title": "TYMLOS label",
          "date": "2026-08-11",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    }
  ]
}
